S
KLRS

SignatureFD’s Kalaris Therapeutics KLRS Stock Holding History

SignatureFD’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27
Closed -$1.34K – 3301
2023
Q3 		$1.34K Buy
+27
New +$1.84K ﹤0.01% 2878
2022
Q4 		– Sell
-10
Closed -$2K – 3430
2022
Q3 		$2K Buy
+10
New +$1.56K ﹤0.01% 2870
2021
Q3 		– Sell
-2
Closed -$1K – 3241
2021
Q2 		$1K Buy
+2
New +$1.03K ﹤0.01% 2870

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

SignatureFD's KLRS Position: Q4 2023 in Review

SignatureFD sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 27 shares — an estimated $1.34K sold.

SignatureFD first reported a position in KLRS in Q2 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • SignatureFD reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • SignatureFD sold 27 Kalaris Therapeutics shares in Q4 2023, an estimated $1.34K.
  • SignatureFD first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 3 quarters.
  • SignatureFD's Kalaris Therapeutics position peaked at $2K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.